HHS Orders FDA to Spare 6 Unproven Peptides as Staff Warns of Safety Risks
Updated
Updated · The Guardian · Oct 28
HHS Orders FDA to Spare 6 Unproven Peptides as Staff Warns of Safety Risks
3 articles · Updated · The Guardian · Oct 28
Summary
A document posted Wednesday tells the FDA not to act against specialty pharmacies selling six injectable wellness peptides, easing access to products the agency has not approved as safe or effective.
Six people familiar with the process said the plan was driven largely by HHS and drew overwhelming opposition from FDA drug staffers, who warned it could weaken the agency’s role in keeping unproven products off the market.
FDA officials had blocked an earlier HHS push to formally deem peptides such as BPC-157 safe for compounding, so the department shifted to an enforcement-discretion approach and added guardrails on sourcing, side-effect reporting and identity testing.
The clash is unusual because compounding decisions normally rest with the FDA, whose scrutiny intensified after the 2012 fungal meningitis outbreak tied to contaminated compounded injections.
The policy also cuts against FDA warnings issued in 2023 and again in July that several of the peptides pose unresolved risks including allergic reactions, kidney damage and possible tumor growth.
Could a temporary HHS peptide policy reduce gray-market harm, or will it blur the line between FDA-approved medicine and experimental injections?
If unapproved peptide injections become easier to get through compounding pharmacies, how will patients know whether access means safety or just less enforcement?